William Porter, MD
Urogynecology and Reconstructive Pelvic Surgery · Charlotte, NCNPI 1750380549
Payments from drug & device makers
Across 473 payments — averaging $374.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$82K
- Astellas Pharma US Inc$70K
- Caldera Medical, Inc$12K
- Axonics, Inc.$3K
- Medtronic$2K
- Boston Scientific$2K
- plus $4K from 20 others
Across 8 payments — averaging $1221.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Coloplast$9K
- Medtronic$630
What the payments were for
- Consulting fees$41,14226%
- Speaking & faculty fees$54,88835%
- Travel & lodging$27,37817%
- Food & beverage$14,5829%
- Education$18,51512%
- Gifts$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 145 | $82,269 |
| Astellas Pharma US Inc | 99 | $70,427 |
| Caldera Medical, Inc | 26 | $12,377 |
| Axonics, Inc. | 27 | $3,063 |
| Medtronic(2 entities) | 38 | $2,480 |
| Boston Scientific | 23 | $2,449 |
| Teleflex LLC | 5 | $1,269 |
| AbbVie(2 entities) | 21 | $544 |
| Sumitomo Pharma America, Inc. | 22 | $482 |
| Pfizer | 20 | $398 |
| Urovant Sciences Inc | 17 | $369 |
| Abbott | 3 | $298 |
| Coopersurgical, Inc. | 4 | $258 |
| Escala Medical Inc. | 1 | $168 |
| Femselect Inc. | 1 | $75 |
| Therapeuticsmd, Inc. | 4 | $66 |
| AMAG Pharmaceuticals, Inc. | 4 | $64 |
| Convatec Inc. | 2 | $51 |
| Johnson & Johnson | 2 | $39 |
| Palette Life Sciences, Inc. | 1 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $31 |
| Laborie Medical Technologies Corp. | 1 | $28 |
| Millicent US Inc | 1 | $24 |
| Provepharm Inc. | 1 | $21 |
| Hollister Incorporated | 1 | $15 |
| Merck | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$177,315 in reported general payments places this provider in the 85th percentile of 35 urogynecology and reconstructive pelvic surgery providers in North Carolina.
See all urogynecology and reconstructive pelvic surgery providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 287 | $193,631 |
| GemtesaVibegron | 240 | $185,989 |
| ElmironPentosan Polysulfate Sodium | 21 | $19,853 |
| PremarinEstrogens, Conjugated | 42 | $16,995 |
| Methenamine Hippurate | 164 | $10,337 |
| Estradiol | 133 | $8,764 |
| Solifenacin Succinate | 88 | $4,293 |
| Darifenacin ErDarifenacin Hydrobromide | 23 | $2,828 |
| Silodosin | 26 | $2,505 |
| Trospium Chloride | 37 | $1,400 |
| Trimethoprim | 39 | $1,010 |
| Bethanechol Chloride | 13 | $880 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 71 | $851 |
| Oxybutynin Chloride | 30 | $791 |
| Cephalexin | 98 | $730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $70,427 | $193,631287 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $482 | $185,989240 claims |
| PfizerPremarin | $398 | $16,99542 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 35 urogynecology and reconstructive pelvic surgery providers in North Carolina.
Other urogynecology and reconstructive pelvic surgery in Charlotte
- Cary FishburneCharlotte$231K
- Erinn MyersCharlotte$30K
- Kevin SteppCharlotte$10K
- Nazema SiddiquiDurham$1.1M
- Catherine MatthewsWinston Salem$954K
- Cindy AmundsenDurham$323K
- Amie KawasakiDurham$27K
- Jennifer WuChapel Hill$14K
- Rahul DuttaWinston Salem$13K
- Sarah BradleyCary$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.